[13C6]-Clopidogrel, racemic mixture

[13C6]-Clopidogrel, racemic mixture is a chemical compound that is primarily used as an antiplatelet agent. It is a chiral molecule that contains carbon-13 isotopes. This compound is a modified version of clopidogrel, which is a commonly used medication for the prevention of blood clots in patients with cardiovascular diseases. Clopidogrel belongs to a class of drugs known as thienopyridines, which act by irreversibly inhibiting the P2Y12 receptor on platelets. This receptor is responsible for the activation of platelets and the formation of blood clots. By inhibiting this receptor, clopidogrel prevents the aggregation of platelets, thereby reducing the risk of blood clots. [13C6]-Clopidogrel, racemic mixture is a stable isotope-labeled analog of clopidogrel that is used in pharmacokinetic studies to determine the metabolism and bioavailability of the drug. The carbon-13 isotopes in the compound allow for the tracking of the drug's metabolic fate in the body using sophisticated analytical techniques. Chemically, [13C6]-Clopidogrel, racemic mixture is a mixture of two enantiomers that are mirror images of each other. The enantiomers have different pharmacological properties, with one being more active than the other. The racemic mixture contains equal amounts of both enantiomers, making it a versatile tool for studying the pharmacokinetics of clopidogrel in different patient populations. In conclusion, [13C6]-Clopidogrel, racemic mixture is a valuable tool in drug development and research that is used to gain a better understanding of the pharmacokinetics of clopidogrel. Its stable isotope-labeled analog allows for accurate and precise tracking of the drug's metabolic fate, making it an essential component of pharmacological studies.